6/21/2013

Mirabilis Medica has obtained as much as $13 million in Series A1 financing, which it will use to develop its high-intensity focused ultrasound device designed to treat uterine fibroids. The Bothell, Wash.-based company also has appointed Jens Quistgaard to serve as its new CEO.

Related Summaries